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Regulation of the Oncogenic
Activity of BCR-ABL by a Tightly
Bound Substrate Protein RIN1
Daniel E. H. Afar,* Limin Han,² Jami McLaughlin,* BCR-ABL is a chimeric oncogene generated by the
reciprocal chromosomal translocation t(9;22) (q34;q11)Stephane Wong,³ Ajay Dhaka,² Kalindi Parmar,‖
(reviewed by Kurzrock et al., 1988). BCR sequences areNaomi Rosenberg,‖ Owen N. Witte,*³§
fused upstream of c-abl, resulting in the activation ofand John Colicelli²³
Abl tyrosine kinase activity (Konopka et al., 1984). Two*Department of Microbiology and Molecular
BCR-ABL isoforms, P185 and P210, are associated withGenetics
the pathology of human acute lymphocytic and chronic²Department of Biological Chemistry
myelogenous leukemias (Kurzrock et al., 1988).³Molecular Biology Institute
BCR-ABL is a complex molecule with multiple func-§Howard Hughes Medical Institute
tional domains, including a BCR oligomerization andUniversity of California, Los Angeles
SRC homology 2 (SH2)±interacting region, Abl-derivedLos Angeles, California 90095
SH3 and SH2 domains, a tyrosine kinase domain, and‖Departments of Molecular Biology and
an actin-binding region at the carboxyl terminus (re-Microbiology and Pathology
viewed by Laneuville, 1995). The SH3 domain, whichTufts University School of Medicine
binds proline-rich sequences, and the SH2 domain,Boston, Massachusetts 02115
which binds phosphotyrosine-containing peptide se-
quences, provide potential docking sites for BCR-ABL
targets. The BCR sequences activateAbl kinase activity,
Summary which is the most critical determinant of transforming
activity (Lugo et al., 1990; McWhirter and Wang, 1991;
RIN1 was originally identified by its ability to physically Muller et al., 1991). Activation of Ras is an essential
bind to and interfere with activated Ras in yeast. Para- event for transformation by BCR-ABL (Sawyers et al.,
doxically, RIN1 potentiates the oncogenic activity of 1995). This is achieved by the binding and activation of
the BCR-ABL tyrosine kinase in hematopoietic cells Shc, Crkl, Grb-2, and Grap, which are adapter proteins
and dramatically accelerates BCR-ABL±induced leu- involved in redundant pathways for Ras activation
kemias in mice. RIN1 rescues BCR-ABL mutants for (Pendergast et al., 1993b; Puil et al., 1994; Matsuguchi
transformation in a manner distinguishable from the et al., 1994; Oda et al., 1994; Tauchi et al., 1994; ten
cell cycle regulators c-Myc and cyclin D1 and the Ras Hoeve et al., 1994; Goga et al., 1995; Feng et al., 1996).
connector Shc. These biological effects require tyro- Mutations in the Grb-2±binding site (Y177F) (Pender-
sine phosphorylation of RIN1 and binding of RIN1 to gast et al., 1993b; Puil et al., 1994), in the phosphotyro-
the Abl-SH2 and SH3 domains. RIN1 is tyrosine phos- sine-binding site of the SH2 domain (R552L) (Afar et al.,
phorylated and is associated with BCR-ABL in human 1994), and in the major kinase autophosphorylation site
and murine leukemic cells. RIN1 exemplifies a new (Y793F) (Pendergast et al., 1993a) have been shown to
reduce BCR-ABL±mediated transformation. The trans-class of effector molecules dependent on the con-
forming activity of the SH2 mutant is specifically re-certed action of the SH3, SH2, and catalytic domains
stored by increasing the gene dosage of c-myc (Afar etof a cytoplasmic tyrosine kinase.
al., 1994) or cyclin D1 (Afaret al., 1995), while transforma-
tion by the Grb-2±binding site mutant is rescued byIntroduction
increasing Shc dosage (Goga et al., 1995). These differ-
ential rescue experiments indicate that multiple signalsThe biological activity of tyrosine kinases is dependent
must be activated for cellular transformation, which in-on their ability to activate downstream signaling path-
clude signals to cell cycle regulators and Ras.ways. This function is often mediated by the physical
Ras is a member of a family of small GTP-binding
binding of tyrosine kinases with their targets via con-
proteins that are central components of many tyrosine
served protein domains (Pawson, 1995). Multiple tyro-
kinase signaling pathways. They function by activating
sine kinase substrates and binding proteins have been downstream effector molecules, which include serine/
identified (reviewed by Kazlauskas, 1994; Brown and threonine kinases (Van Aelst et al., 1993; Vojtek et al.,
Cooper, 1996), but not all prove to be biologically rele- 1993; Manser et al., 1994; Chou and Blenis, 1996).
vant. However, generating mutations in the tyrosine ki- Recently, a novel Ras-binding protein was identified
nases or their targets that prevent physical association from a human cDNA library in a Ras interference screen
is an effective means to determine the importance of in yeast (Han and Colicelli, 1995). The RIN1 protein
their interaction (Valius and Kazlauskas, 1993). We and blocked RAS2V19-induced cell death by interacting di-
others have developed a genetic strategy to analyze rectly with the effector domain of GTP-bound RAS. Se-
signaling by activated tyrosine kinases (Roussel et al., quencing of RIN1 revealed the presence of an amino-
1991; Afar et al., 1994, 1995; Goga et al., 1995; Roussel et terminal SH2 domain and a proline-rich region (Han et
al., 1995). Partial loss-of-function mutants of a tyrosine al., 1997). The proline-rich region in RIN1 is homologous
kinase are tested for rescue of the wild-type phenotype to the Abl-SH3±binding consensus (Ren et al., 1993;
by increasing the gene dosage of a regulator or effector Rickles et al., 1994; Alexandropoulos et al., 1995). This
molecule. Increasing the gene expression of effectors raised the possibility that RIN1 can interact with different
compensates for the loss of a specific component or signaling molecules, including Ras and tyrosine kinases
such as Abl.reduced strength of the tyrosine kinase signal.
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Expression of BCR-ABL in Rat-1 cell fibroblasts per-
mits anchorage-independent growth in soft agar (Lugo
and Witte, 1989) that is dependent on a critical level of
Ras activity (Mandanas et al., 1993; Pendergast et al.,
1993b, Sawyers et al., 1995). The Ras interference activ-
ity of RIN1 predicted that it would function as an indirect
inhibitor of BCR-ABL function. Paradoxically, we found
that BCR-ABL transformation activity is augmented by
increased gene dosage of RIN1. Overexpression of RIN1
increased BCR-ABL ±mediated transformation of hema-
topoietic cells and increased the leukemogenic activity
of BCR-ABL in mice. RIN1 is found complexed with
BCR-ABL in human leukemia±derived cell lines.Deletion
of the Ras-binding region of RIN1 increased its syner-
gistic activity with BCR-ABL. This transformation syn-
ergy required tyrosine phosphorylation of RIN1 and its
physical binding to BCR-ABL, supporting a role as a
novel binding and effector molecule for BCR-ABL.
Results
RIN1 Accelerates Lymphoid Cell Transformation
by BCR-ABL
RIN1 interferes with activated RAS alleles in yeast.Since
BCR-ABL is dependent on Ras for transforming activity,
we expected that expression of RIN1 would lead to a
block in BCR-ABL±mediated transformation. To test the
ability of RIN1 to block BCR-ABL, we constructed ret-
roviral vectors (Afar et al., 1995; Sawyers et al., 1995)
that allow the simultaneous expression of RIN1 and
P185 BCR-ABL. A RIN1 mutant, RIN1N (amino acids
1±295), with a deletion of the carboxyl-terminal Ras±
interacting region, was used as a control. Retrovirally Figure 1. Stimulation of P185 Bone Marrow Transformation by RIN1
and RIN1Nmediated expression of BCR-ABL into primary mouse
Retroviruses containing wild-type P185 linked in cis to either neo,bone marrow results in transformation of pre±B cells in
RIN1, orRIN1N were generated.Expression of neo, RIN1, and RIN1Nstromal cell dependent cultures (McLaughlin et al.,
was driven by the retroviral LTR, while expression of P185 was1987). The growth rate of pre±B cells from infected mar-
controlled by the tk promoter. Primary mouse bone marrow was
row is directly dependent on the strength of the tyrosine infected with the retroviruses and plated in liquid culture. Four repli-
kinase activity (McLaughlin et al., 1989). To determine cates of each sample were monitored for pre±B cell growth. Cell
whether RIN1 affects hematopoietic cell transformation counts were performed at different time intervals after infection.
Cultures with more than 2 3 107 cells are confluent.by P185 BCR-ABL, mouse bone marrow was infected
with retroviruses encoding different gene combinations.
Liquid cultures were plated in quadruplicate and were either neo, RIN1, or RIN1N. Two days after infection, the
monitored for pre±B cell growth. Instead of interfering cells were removed from growth factor containing media
with P185-mediated transformation, expression of full- and were plated onto 96-well plates. In the absence of
length RIN1 resulted in an unexpected acceleration of growth factor or P210, DAGM cells die. In the presence
P185-mediated transformation (Figure 1). Deletion of the of P210, 6 of 96 wells of DAGM cells become GM-CSF
Ras-interacting region of RIN1 increased the potency of independent (Table 1 and Goga et al., 1995). Coexpres-
this effect. Cells coexpressing RIN1N with P185 reached sion of P210 with RIN1 increased theefficiency of growth
saturation densities (1±2 3 107 cells/culture) 2 days prior factor independence 4- to 5-fold, permitting growth in
to cells coexpressing P185 with RIN1. 30 of 96 wells. RIN1N increased P210-mediated growth
factor independence more than 10-fold, resulting in
growth in about 90 of 96 wells (Table 1).The Efficiency of Growth Factor Independence
of Myeloid Cells Induced by BCR-ABL
Is Increased by RIN1 RIN1 Accelerates BCR-ABL±Induced Leukemias
in MiceP210, the larger BCR-ABL isoform, is predominantly ex-
pressed in leukemias of the myeloid lineage (Kurzrock Several murine models have been developed to study
BCR-ABL±induced leukemias. These includegenerationet al., 1988). To test the effect of coexpression of RIN1
and RIN1N with P210, we used the granulocyte/macro- of transgenic mice expressing BCR-ABL (Heisterkamp
et al., 1990) or reconstitution of lethally irradiated micephage colony-stimulating factor (GM-CSF)±dependent
myeloid cell line DAGM (Rennick et al., 1987). DAGM with BCR-ABL±expressing bone marrow (Daley et al.,
1990; Elefanty et al., 1990; Kelliher et al., 1990, 1991;cells were infected with retroviruses encoding P210 with
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Table 1. Induction of Growth Factor Independence of DAGM specific point mutations in functional domains of BCR-
Cells by BCR-ABL and RIN1 ABL. Point mutants in the Grb-2±binding site of the BCR
region (Y177F), the phosphotyrosine-binding site of theRetrovirus Experiment 1 Experiment 2
SH2 domain (R552L), and the major kinase autophos-Mock 0/96 0/96
phorylation site (Y793F) are defective in transformingRIN1 tk neo 0/96 0/96
Rat-1 cells despite retaining tyrosine kinase activityneo tk P210 6/96 7/96
(Pendergast et al., 1993a, 1993b; Afar et al., 1994). TheRIN1 tk P210 31/96 27/96
RIN1N tk P210 86/96 93/96 SH2 mutant can be rescued for transforming activity by
increasing the gene dosage of c-myc (Afar et al., 1994)The ability of DAGM cells to be rendered growth factor independent
or cyclin D1 (Afar et al., 1995). Increasing the expressionfollowing expression of P210 BCR-ABL with neo, RIN1, or RIN1N
was determined in two independent experiments. Wells that demon- of the adaptor protein Shc can rescue the Grb-2±binding
strated the outgrowth of factor±independent cells after 14 days in mutant for transformation (Goga et al., 1995).
culture were scored positive. To determine whether RIN1 exhibits rescue activity
similar to or distinct from that of c-Myc or cyclin D1,
different RIN1 forms were coexpressed with the alterna-Scott et al., 1991; Gishizky et al., 1993). To investigate
tive P185 point mutants in Rat-1 fibroblasts. Infectedwhether RIN1 or RIN1N accelerates BCR-ABL±induced
Rat-1 cells were harvested for protein analysis and plat-
leukemias, sublethally irradiated CB.17scid/scid (severe
ing in soft agar. Western analysis showed comparable
combined immunodeficient) mice were reconstituted
expression levels of P185 in each sample and similar
with BALB/c-derived whole bone marrow infected with
expression levels of RIN1 forms. Elevated expression
titer-matched viruses of wild-type P185 plus neo, RIN1,
of full-length RIN1 increased Rat-1 cell transformation
or RIN1N. A fraction of infected marrow was plated in
by P185 Y177F from an average of 30 colonies to an
liquid culture to confirm the transfer and expression of
average of 80 colonies (Table 2). Expression of P185
BCR-ABL by monitoring pre±B cell transformation (data
Y793F in Rat-1 cells causes the growth of fewer than
not shown). In all cases, pre±B cell transformation was 10 colonies in agar. In the presence of RIN1, the number
observed with kinetics, as described in Figure 1. of colonies increased by greater than a log, to an average
In four independent experiments, 25% of mice receiv- of 100 colonies (Table 2). No increase in soft agar colo-
ing P185 with neo developed leukemia within the 90- nies was detected when RIN1 was coexpressed with
day period of observation (Figure 2). In contrast, more the SH2 mutant of P185. Since expression of wild-type
than 60% of mice receiving bone marrow coexpressing P185 in Rat-1 cells results in the growth of 500 colonies
RIN1 with P185 and more than 80% of mice expressing in agar, overexpression of RIN1 did not further increase
RIN1N with P185 succumbed to leukemias within 30±80 colony growth (Table 2).
days after reconstitution (Figure 2). All leukemic mice Expression of RIN1N caused a striking rescue of the
displayed splenomegaly, and in some cases lymph kinase autophosphorylation mutant (Table 2). Colonies
nodes were enlarged (to 4±5 times normal size). Fluores- growing in agar as a result of RIN1N coexpression with
cence activated cell sorting analysis using antibodies P185 Y793F were as large (0.5 ±3 mm in diameter) and
directed to the B cell marker B220 showed that the as numerous as colonies derived from cells expressing
mice exhibited lymphocytic leukemias. Western blotting an equal level of wild-type P185 (50-fold more colonies
analysis of cell lysates from spleen, bone marrow, and than cells expressing P185 Y793F alone). This demon-
lymph nodes showed expression of P185, RIN1, and strates that RIN1N expression restored wild-type±like
RIN1N (data not shown). These data demonstrate that transformation activity to the autophosphorylation mu-
RIN1 expression effectively potentiates the develop- tant. RIN1N was also effective in synergizing with P185
ment of BCR-ABL ±mediated leukemia. Y177F, increasing its activity 10-fold (Table 2). The colo-
nies were large (0.5±2 mm in diameter) and the media
Differential Rescue of P185 Point Mutants with RIN1 was significantly acidified after 3 weeks in culture. Cells
BCR-ABL is known to activate multiple signals for trans- coexpressing P185 R552L and RIN1N exhibited a small
(3±5 fold) increase in colony formation but showed noformation. Some of these signals can be abrogated by
Figure 2. Kaplan-Meyer Plot of Leukemic
Mice Expressing BCR-ABL with RIN1
Survival rates of lethally irradiated SCID mice
reconstituted with bone marrow infected with
retroviruses encoding P185 with neo, RIN1,
or RIN1N. Leukemic diagnosis was based on
gross and microscopic assessment. Cells
wereclassified as lymphoid based on expres-
sion of the B cell marker B220. Mice reconsti-
tuted with bone marrow expressing RIN1 or




Table 2. Rat-1 Transformation by BCR-ABL Mutants with RIN1 To test whether autophosphorylation activity is signifi-
cantly altered, BCR-ABL was immunoprecipitated withNumberof Soft Agar Colonies/
anti-Abl antibodies from lysates of cells coexpressing104 Cells
Rescuing Gene the different P185 forms with RIN1 or RIN1N. Autophos-
phorylation activity of P185 proteins was assayed inP185 Form neo RIN1 RIN1N
vitro on the immunoprecipitates and analyzed by SDS±
neo ,10 ,10 ,10 polyacrylamide gel electrophoresis (SDS-PAGE) with
P185 500 500 .1000
subsequent autoradiography. The results showed that(wild type)
P185 autophosphorylation was not significantly different
P185 Y177F 30 80 300
in the presence or absence of the RIN1 forms (Figure(Grb-2 site mutant)
3). However, full-length RIN1 and RIN1N coimmunopre-
P185 R552L ,10 10 50 cipitated with P185 and were tyrosine phosphorylated
(SH2 mutant)
during the in vitro kinase reaction (Figure 3). This activity
P185 Y793F ,10 100 600 depended on the SH2 domain of BCR-ABL, since muta-
(Auto-phos. mutant) tion of the SH2 domain significantly decreased the asso-
Rat-1 cells were infected with retroviruses encoding different BCR- ciation and phosphorylation of RIN1 molecules. The
ABL forms with either neo, RIN1, or RIN1N. Cells were plated in soft kinase autophosphorylation and Grb-2±binding site mu-
agar at 5 3 104 cells/plate in media containing 10% FBS and were tants coimmunoprecipitated and phosphorylated the
incubated for 3 weeks. The number of colonies represent the aver-
RIN1 forms with efficiency equal to that of wild-typeage colony counts of two to five separate experiments rounded off
P185 (data not shown).to two significant figures.
To determine whether RIN1 and RIN1N are tyrosine
phosphorylated in vivo, different P185 forms were coex-
media acidification (Table 2). The colonies were small, pressed with neo, RIN1, or RIN1N in Rat-1 fibroblasts.
with average diameters of less than 0.5 mm. Western blotting analysis of cell lysates using anti-phos-
photyrosine antibodies showed that both RIN1 andThe P185 point mutants retain their ability to transform
RIN1N were the major tyrosine-phosphorylated speciesprimary mouse bone marrow cells (Goga et al., 1995).
in BCR-ABL±expressing cells (Figure 4). Since RIN1 mol-However, the latency of pre±B cell outgrowth and at-
ecules failed to coimmunoprecipitate with the P185 SH2tainment of saturation growth density (1±2 3 107 cells/
mutant, we expected to detect no tyrosine phosphoryla-culture) are delayed in cultures expressing the P185
tion of RIN1 molecules in cells expressing the SH2 mu-mutants. To test whether their hematopoietic transfor-
tant of P185. However, RIN1 molecules were also signifi-mation activity can be augmented with RIN1 or RIN1N,
cantly tyrosine phosphorylated in these cells (Figure 4).the P185 mutants were coexpressed with the different
This result suggests that the SH2 domain of BCR-ABLRIN1 genes in primary mouse bone marrow. Previously,
is not essential for recognition and phosphorylation ofwe have shown that cyclin D1 stimulates the ability of
RIN1, but it is important for formation of stable com-P185 R552L to transform bone marrow (Afar et al., 1995).
plexes with RIN1.Coexpression of RIN1 or RIN1N accelerated pre±B cell
outgrowth with either the kinase autophosphorylation
mutant or the Grb-2 ±binding site mutant (data not
shown). Much weaker synergy was observed when RIN1
was coexpressed with the P185 SH2 mutant. These re-
sults suggest that RIN1 functions to replace or compen-
sate for signals dependent on the autophosphorylation
site and Grb-2 binding.
The Mechanism of RIN1 Action Involves Tyrosine
Phosphorylation of RIN1 and Physical
Interaction with BCR-ABL
The major kinase autophosphorylation site in BCR-ABL
(Y793) is homologous to Y416 in c-Src, which serves to
activate the intrinsic kinase activity (Piwnica-Worms et
al., 1987; Kmiecik and Shalloway, 1987). In BCR-ABL,
mutation of the autophosphorylation site results in a
30%±50% decrease in in vitro kinase activity (Pender-
gast et al., 1993a; Afar et al., 1994). Although the phos- Figure 3. Association of RIN1 and RIN1N with BCR-ABL
photyrosine content of cells expressing the auto- Immune complex kinase assays were performed as described in
phosphorylation mutant is not significantly different Experimental Procedures. 293T cell lysates were immunoprecipi-
tated with anti-Abl antibodies and were assayed for in vitro phos-from that of cells expressing wild-type BCR-ABL, their
phorylation by the addition of 32P-g ATP. Molecular size markers aretransforming activity is profoundly decreased (Pender-
indicated in kilodaltons. The positions of P185, RIN1, and RIN1Ngast et al., 1993a; Afar et al., 1994). The rescue of P185
are indicated. Samples are wild-type P185 with neo (lane 1), withY793F biological activity with RIN1 could be due to a
RIN1 (lane 2), and with RIN1N (lane 3); P185 R552L (SH2 mutant)
recovery of this signal by either increasing BCR-ABL with neo (lane 4), with RIN1 (lane 5), and with RIN1N (lane 6); and
kinase activity or by substituting for the loss of a poten- P185 Y793F (kinase autophosphorylation mutant) with neo (lane 7),
with RIN1 (lane 8), and with RIN1N lane (9).tial effector that interacts with phosphorylated Y793.
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Figure 4. Phosphotyrosine Analysis of RIN1 and RIN1N
Rat-1 cells were infected with retroviruses that coexpress neo, RIN1,
or RIN1N with the different P185 forms. The cells were lysed directly
in SDS-containing sample buffer (at 1008C) 72 hr postinfection. The
lysates wereresolved on SDS-PAGE (10% polyacrylamide) andwere
transferred to nitrocellulose. The blots were probed with antibodies
directed to BCR (a-BCR), RIN1 (a-RIN1), and phosphotyrosine
(a-P-TYR). Molecular size markers are indicated in kilodaltons. The Figure 5. Deletion of the Abl-SH3 Domain Prevents BCR-ABL/RIN1
positions of P185, RIN1, and RIN1N are indicated. The samples Association and Tyrosine Phosphorylation of RIN1N
include neo with wild-type P185 (lane 1), P185 Y177F (lane 2), P185 (A) Neo or RIN1 were coexpressed with P185 or P185DSH3 in 293T
R552L (lane 3), and P185 Y793F (lane 4); RIN1 with wild-type P185 cells and were analyzed by immune complex kinaseassays. Molecu-
(lane 5), P185 Y177F (lane 6), P185 R552L (lane 7), and P185 Y793F lar size markers are indicated in kilodaltons (KD). The positions of
(lane 8); and RIN1N with wild-type P185 (lane 9), P185 Y177F (lane P185 and RIN1 are indicated. The samples include wild-type P185
10), P185 R552L (lane 11), and P185 Y793F (lane 12). with neo (lane 1) or RIN1 (lane 2) and P185DSH3 with neo (lane 3)
or RIN1 (lane 4).
(B) Cell lysates were prepared from Rat-1 cells coexpressing RIN1NStructural Requirements for Tyrosine
with different P185 forms and were analyzed using anti-Abl (a-ABL),
Phosphorylation of RIN1 anti-RIN1 (a-RIN1), and anti-phosphotyrosine (a-P-TYR) antibodies.
The amino terminus of RIN1 includes a proline-rich do- The samples include mock-infected cells (lane 1) and cells coex-
main with high homology to the Abl-SH3 domain con- pressing RIN1N with wild-type P185 (lane 2), P185 Y177F (lane 3),
P185 R552L (lane 4), P185 Y793F (lane 5), and P185DSH3 (lane 6).sensus binding sequence (Ren et al., 1993; Rickles et
al., 1994; Alexandropoulos et al., 1995). Recently, we
have shown that a peptide derived from the amino-
terminal region of RIN1, which includes the sequence
PPAVPPPPVP binds to GST-Abl-SH3 fusion proteins in and RIN1N to increase the transformation activity of
an alternative abl oncogene, v-abl. The v-Abl proteinvitro (Han et al., 1997). To determine whether the Abl-
SH3/RIN1 amino-terminal interaction contributes to the exhibits an amino-terminal fusion to viral gag sequences
and a deletion in the SH3 domain (reviewed by Rosen-ability of BCR-ABL to interact with RIN1, the Abl-SH3
domain was deleted in P185. RIN1 was coexpressed berg and Witte, 1988). Coexpression of RIN1 or RIN1N
with either v-Abl or a transformation defective kinasewith P185DSH3 in 293T cells to test for coimmunopre-
cipitation and in vitro phosphorylation. The results show autophosphorylation mutant of v-Abl did not result in a
significant increase in transformation activity in eitherthat deletion of the SH3 domain blocked physical asso-
ciation of RIN1 with P185, as determined by an immune NIH 3T3 cells or primary mouse bone marrow cells (data
not shown). In addition, no complementation was ob-complex in vitro kinase assay (Figure 5A). In vivo tyrosine
phosphorylation of RIN1N was greatly reduced when served with carboxyl terminal v-Abl truncation mutants,
which are severely compromised in lymphoid cell trans-RIN1N was coexpressed in Rat-1 cells with P185DSH3
(Figure 5B). In addition, no significant increase in cellular formation. Combined with the P185DSH3 data, these
results suggest that RIN1 phosphorylation and biologi-transformation was observed when RIN1N was coex-
pressed with P185DSH3 (data not shown). cal activity require an interaction with the Abl-SH3
domain.To confirm this result, we tested the ability of RIN1
Immunity
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motifs include the minimum sequence requirement for
SH3-domain binding (reviewed by Feller et al., 1994)
and may explain the retention of binding and biological
activity of RIN1ND.
Tyrosine Phosphorylation of the RIN1 Amino
Terminus Is Required for Biological Activity
The sequence of the RIN1 amino terminus reveals the
presence of three potential tyrosine phosphorylation
sites: Y36, Y121, and Y148 (Han et al., 1997). The se-
quence following Y36 (YDVP) is identical to the se-
quence following multiple tyrosine phosphorylation
sites in the Src kinase substrate p130CAS (Sakai et al.,
1994) and its relative Sin (Alexandropoulos and Balti-
more, 1996). To determine which of these potential tyro-
sine phosphorylation sites are required for RIN1N activ-
ity, all sites were mutated to phenylalanine either singly
or in combination as a triple mutant. Coexpression of
the different RIN1N phosphorylation mutants with P185
Y793F in 293T cells showed that single point mutants
coimmunoprecipitated with P185 Y793F and served as
invitro substrates (Figure6A). Totest for biological activ-
ity, each mutant was stably coexpressed with P185
Y793F in Rat-1 cells. Analysis of soft agar growth
showed that the single point mutants rescued P185
Y793F transforming activity (Figure 6B). The triple phos-
phorylation mutant failed to rescue transforming activity
despite an expression level equal to that of the other
mutants (Figure 6A). Therefore, the three potential tyro-
sine phosphorylation sites in RIN1N are redundant for
biological activity.
RIN1 Is Tyrosine Phosphorylated and Associated
with BCR-ABL in Human Leukemic Cells
BCR-ABL expression naturally occurs in hematopoietic
Figure 6. Rescue of P185 Y793F with RIN1N Mutants
cells and is associated with the pathogenesis of human
RIN1N mutants were generated with mutations in the potential tyro-
CML and ALL. To determine whether RIN1 is tyrosinesine phosphorylation sites or the proline-rich region and were tested
phosphorylated and a potential regulator of BCR-ABLfor biochemical and biological interaction with the autophosphoryla-
in human leukemia, we analyzed the association of RIN1tion mutant of P185.
(A) Cell lysates from cells coexpressing P185 Y793F with different with BCR-ABL in several Philadelphia chromosome
RIN1N mutants were analyzed by immune complex kinase assays (Ph1)±positive leukemic cell lines. RIN1 expression was
(as described for Figure 4) and Western blotting using anti-RIN1 detected in the three Ph1-positive leukemic cell lines
antibodies (aRIN1). Molecular size markers are indicated in kilodal-
tested (K562, ALL1, and KCL22). The highest levels oftons. The samples include P185 K619R (kinase inactive BCR-ABL)
RIN1 expression were detected in KCL22 cells (data notwith RIN1N (lane 1); P185 Y793F with RIN1N (lane 2), RIN1N Y36F
shown).(lane 3), RIN1N Y121F (lane 4), RIN1N Y148F (lane 5), RIN1N Y/F TM
(triple tyrosine mutant) (lane 6), and RIN1ND (lane 7). Endogenous RIN1 and P210 BCR-ABL were immuno-
(B) Rat-1 cells expressing the different RIN1N mutants were plated precipitated with anti-RIN1N or anti-Abl antibodies from
in soft agar at 5 3 104 cells/plate in media containing 10% FBS. KCL22 cell lysates. The immune complexes were sub-
The number of colonies represent the average colony counts of
jected to in vitro kinase reactions and analyzed by SDS-duplicate plates after 3 weeks in culture.
PAGE. The results show that P210 coimmunoprecipi-
tates with and phosphorylates a 90 kDa protein (lane 1).
Anti-RIN1N immunoprecipitates also contain two phos-
phoproteins with molecular weights of 210 and 90 kDaWhen the presumed proline-rich SH3-binding region
in RIN1N (residues 244±295) was deleted (RIN1ND), (Figure 7A, lane 2). The identity of the 210 and 90 kDa
proteins as P210 BCR-ABL and RIN1 were confirmedcoexpression with P185 Y793F still resulted in coimmu-
noprecipitation and phosphorylation of RIN1ND in vitro, by reimmunoprecipitating the samples with either anti-
Abl or anti-RIN1N antibodies (Figure 7A, lanes 3±6).although at a reduced efficiency ( lane 7), and tyrosine
phosphorylation of RIN1N in vivo (data not shown). Bio- To determine whether RIN1 is tyrosine phosphory-
lated in KCL22 cells in vivo, RIN1 and P210 were immu-logical rescue of P185 Y793F was also observed (Figure
6B). This result suggests that RIN1ND may interact with noprecipitated from cell extracts and subjected to phos-
photyrosine analysis by Western blotting. Anti-RIN1Nthe Abl-SH3 domain via an alternate region. The amino
terminus of RIN1 contains four additional PXXP motifs and anti-Abl immunoprecipitates show a remarkably
similar phosphotyrosine pattern of at least three distinctat residues 12±15, 49±52, 201±204, and 227±230. These
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Discussion
RIN1 Accelerates BCR-ABL±Mediated Leukemias
by Activating a Novel Signaling Pathway
Here we describe the identification of RIN1 as a novel
substrate effector molecule for BCR-ABL. The dramatic
biological activity in in vitro hematopoietic transforma-
tion assays and especially in the mouse leukemogenesis
assay demonstrates the functional importance of RIN1.
The significant expression levels in human leukemic cell
lines suggest that RIN1 contributes to the pathogenesis
of human BCR-ABL±induced leukemias.
RIN1 expression rescued cellular transformation ac-
tivity of both the autophosphorylation site and Grb-2
site mutants of BCR-ABL. The physical interaction of
RIN1 with BCR-ABL may replace an interaction with a
proximal effector that is lost by mutation of the auto-
phosphorylation site. RIN1 may function as an adaptor
protein that recruits molecules to form a signaling com-
plex, a role proposed for the tyrosine kinase substrates
Sin (Alexandropoulos and Baltimore, 1996), p130Cas (Sa-
kai et al., 1994), and p62dok (Carpino et al., 1997; Yama-
nashi and Baltimore, 1997). RIN1 itself contains a func-
tional SH2 domain in the amino terminus and exhibits
three potential tyrosine phosphorylation sites that could
function as protein docking sites (Han et al., 1997).
RIN1 may recover the Grb-2 signaling pathway by
physically recruiting Grb-2 to the BCR-ABL complex.
However, coexpression of RIN1 or RIN1N with either
wild-type P185 or P185 Y177F did not significantly in-
crease Grb-2 association as detected by coimmuno-
precipitation (D. E. H. A. and O. N. W., unpublished data).
This is in contrast to Shc, which rescues P185 Y177F
by recruiting Grb-2 (Goga et al., 1995), and indicates
that RIN1 functions in a distinct pathway that can substi-Figure 7. Tyrosine Phosphorylation of RIN1 and Association with
tute for Grb-2±mediated signaling.P210 BCR-ABL in Human Leukemic Cells
RIN1, through its carboxyl terminus, interacts specifi-Lysates prepared from KCL22 cells were analyzed by (A) immune
complex kinase assays and (B) immune complex Western blot cally with GTP-bound Ras and may serve as a Ras ef-
analysis. fector (Han and Colicelli, 1995). Thus, RIN1 may link
(A) For immune complex kinase analysis, samples were immunopre- BCR-ABL directly to signals downstream of Ras. How-
cipitated using antibodies directed toward Abl (lane 1) and RIN1N
ever, RIN1N does not interact with Ras and is more(lane 2). Anti-Abl immune complexes were reimmunoprecipitated
effective in rescuing BCR-ABL mutants. This suggestsusing antibodies directed toward Abl (lane 3) and RIN1N (lane 4).
a function for RIN1 that may be unrelated to direct RasAnti-RIN1N immune complexes were reimmunoprecipitated using
antibodies directed toward Abl (lane 5) and RIN1N (lane 6). I.P., binding. RIN1 may have a dual purpose in acting as an
immunoprecipitation. effector for both Ras and activated tyrosine kinases. In
(B) Anti-Abl (lanes 1 and 3) and anti-RIN1N (lanes 2 and 4) immune vivo association studies have shown that RIN1 mole-
complexes were analyzed by Western blotting using antibodies di-
cules associated with BCR-ABL do not coimmunopre-rected toward phosphotyrosine (a-P-TYR), Abl (a-ABL), and RIN1
cipitate Ras, and, similarly, Ras associated RIN1 does(a-RIN1). The relative positions of P210 BCR-ABL and RIN1 are
not bind BCR-ABL (L. H. and J. C., unpublished data).indicated.
These alternative functions possibly compete with each
other, helping to explain why full-length RIN1 is less
proteins with molecular weights of 210, 120, and 90 kDa effective in synergizing with BCR-ABL than RIN1N.
(Figure 7B). The identity of the 120 kDa protein is not
known and was not further analyzed. Anti-Abl Western RIN1 Functions by Physical Interaction
analysis of the samples confirms that the 210 and 90 with BCR-ABL
kDa proteins correspond to P210 BCR-ABL and RIN1, Our results show that RIN1 interacts with BCR-ABL by
respectively (Figure 7B). at least three different mechanisms that involve the Abl-
Tyrosine phosphorylation of RIN1 was also detected SH3, SH2, and kinase domains. One possible interpreta-
in K562 and ALL1 cells (data not shown). Since 10 times tion of our results is that the interaction of RIN1 with
more cell lysate was used to immunoprecipitate RIN1 BCR-ABL is initiated by the Abl-SH3 domain, followed
and since the amount of P210 is approximately equiva- by RIN1 tyrosine phosphorylation by the Abl-kinase do-
lent in the anti-Abl and the anti-RIN1 immune com- main and subsequent association of RIN1 with the Abl-
plexes, we estimate that about 10% of BCR-ABL mole- SH2 domain. Abl-SH2 binding is critical for RIN1 func-
tion, since RIN1 phosphorylation alone is insufficientcules are stably associated with RIN1.
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Generation of Virus Stocksfor biological activity. Alternatively, all three interactions
Helper-free retroviruses were generated by transient cotransfectionmay cooperate with each other to promote RIN1±BCR-
of 293T cells (Pear et al., 1993) (provided by D. Baltimore, Massachu-ABL association.
setts Institute of Technology) with retroviral vectors and a Psi2 eco-
Deletion of the Abl-SH3 domain potentiates the trans- tropic packaging vector (Muller et al., 1991). Supernatant from
forming activity of abl oncogenes (Franz et al., 1989; transfected 293T cells was collected 36±50 hr posttransfection. Viral
titers were determined indirectly by measuring protein expressionJackson and Baltimore, 1989; Muller et al., 1991). This
and/or retroviral integration into the genome 48±72 hr after infectiondemonstrates that the Abl-SH3 domain is not essential
of Rat-1 cells by Western blotting (Muller et al., 1991) or Southernfor transformation and suggests that RIN1±Abl interac-
analysis, respectively. Viral stocks were normalized to give equiva-tions may also not be critical for in vitro transformation
lent protein expression for the various samples.
of cells. However, coexpression of RIN1N with BCR-
ABL is as effective as deletion of the SH3 domain of Soft Agar Transformation Assays and Growth Factor
BCR-ABL in increasing transforming activity (D. E. H. Independence Assays
Soft agar transformation assays were performed as described pre-A. and O. N. W., unpublished data). In addition, SH3
viously (Lugo and Witte, 1989; Muller et al., 1991). Retrovirally in-deletions in BCR-ABL are rarely detected in human dis-
fected cells were grown for 48±72 hr and were plated in soft agarease (Soekarman et al., 1990). This suggests that the
at a density of 1 3 104 cells/6 cm dish. The samples were plated in
SH3 domain may provide a unique signal necessary for duplicate in medium containing 10% fetal calf serum. Colonies 0.5
leukemogenesis that may be mediated by molecules mm in diameter or larger were counted 2±3 weeks after plating.
such as RIN1. Growth factor independence assays were performed as pre-
viously described (Goga et al., 1995). DAGM cells were grown inRIN1 may normally interact with cellular forms of Abl
media containing growth factor for 2 days postinfection. Cells wereand other tyrosine kinases that contain SH3 and SH2
then washed twice in media without growth factor and were plateddomains, such as the Src family kinases, which are in-
in 96-well dishes at a density of 1 3 104 cells/well. At 2 weeks
volved in a range of cellular signaling pathways (re- postinfection, wells that demonstrated an outgrowth of factor-inde-
viewed by Erpel and Courtneidge, 1995). c-Abl is ex- pendent cells were scored positive.
pressed in the nucleus and cytoplasm (Van Etten et al.,
Bone Marrow Transformation and Reconstitution1989; Wen et al., 1996), while Src-family kinases and
of Irradiated MiceRIN1 are localized to the cytoplasm and inner surface
Bone marrow was isolated from tibias and femurs of 4±8 week oldof the plasma membrane (Erpel and Courtneidge, 1995;
male BALB/c mice and infected with matched retroviral stocks. Cells
Han and Colicelli, 1995). It may be that during certain were plated at a density of 5 3 106 cells/6 cm dish and the number
stimuli, when c-Abl is induced to relocate to the cyto- of nonadherent pre±B cells were counted 10±14 days postinfection
plasm (Lewis et al., 1996), a normal interaction with RIN1 (McLaughlin et al., 1987). A culture was scored positive if it reached
a cell density of greater than or equal to 1 3 106 cells/culture.may occur. Oncogenic tyrosine kinases, such as BCR-
Saturation density was reached at greater than 1 3 107 cells/culture.ABL, may exploit molecules such as RIN1 to provide
One day prior to reconstitution, severe combined immunodefi-them with aberrant functions and to feed into multiple
cient (SCID) mice were sublethally irradiated with 275 rad. Wholesignaling pathways. Tyrosine phosphorylation of RIN1
bone marrow was isolated and infected with retrovirus as described
and binding to BCR-ABL are clearly detected in human above. Three hours postinfection, the bone marrow was injected
Ph1-positive leukemic cells. These observations, to- intravenously into the tail veins of recipient SCID animals. Animals
gether with the finding that RIN1 accelerates BCR-ABL± were monitored for signs of sickness over a 12-week period. Sick
mice were sacrificed and tissues were analyzed for BCR-ABL, RIN1,induced leukemias in mice, suggests that expression of
and RIN1N expression using Western blotting. Blood and spleenRIN1 in CML contributes to the pathology of thedisease.
samples were analyzed by fluorescence-activated cell sorting.
Blood smears were analyzed by Wright/Giemsa staining.Experimental Procedures
Western BlottingPlasmid Construction and Mutagenesis
Western blotting was performed as described previously (Muller etThe different P185 BCR-ABL forms (Afar et al., 1994) were cloned
al., 1991). Cells were lysed in boiling SDS-containing sample buffer.into the retroviral vector pSRaMSVtk (Muller et al., 1991) using a
Solubilized protein was resolved by SDS-PAGE, transferred to nitro-unique XbaI site 39 to the herpes simplex thymidine kinase (tk) pro-
cellulose filters, and probed with specific antibodies. Samples weremoter. The different RIN1 cDNAs (Han and Colicelli, 1995; L. H. et
analyzed using monoclonal antibodies directed toward ABL (pex5),al., unpublished data) or neo were inserted into a unique EcoRI site
phosphotyrosine (4G10, UBI, Lake Placid, NY), and RIN1 (Transduc-39 to the retroviral LTR and 59 to the tk promoter and BCR-ABL.
tion Laboratories, Lexington, KY) or polyclonal antibodies directedThis vector allows the simultaneous expression of both genes from
toward the amino terminus of RIN1 (L. H. et al., unpublished data)a single retrovirus (Sawyers et al., 1995).
or BCR (Timmons and Witte, 1989).The RIN1ND mutant was created from pGEX-RIN1N (L. H. et al.,
unpublished data) by digestion with HindIII and KpnI, which releases
Immune Complex Kinase Assaysa 150 bp fragment encoding the proline-rich region. The plasmid
For in vitro kinase assays, 293T cells were transfected with retroviralwas religated in the presence of oligonucleotide (AGCTTGTAC) and
vectors expressing the different cDNAs.Cells were lysed in immuno-dATP to generate pGEX-RIN1ND. This mutant was then cloned into
precipitation buffer (10 mM Tris [pH 7.5], 130 mM NaCl, 20 mM NaF,the retroviral vector.
1 mM sodium vanadate, 1% Triton X-100, 10% glycerol) at 5 3 106The RIN1 point mutants were created using in vitro oligonucleo-
cells/ml and were clarified by centrifugation (100,000 3 g) for 30tide-directed mutagenesis (Muta-Gene, BioRad) on single-stranded
min. The lysates were incubated with polyclonal antibodies directedtemplate of RIN1N in pBluescriptSK (Stratagene). The oligonucleo-
toward Abl (pex5) for 1 hr with subsequent immunoprecipitationtides used to generate each mutation were 59-AGGACCCACTGTTC
using protein A±Sepharose beads (Pharmacia). The immunoprecipi-GACGTGCCCAAT (Y36 to F), 59-TCTCCAGCCACTTCATCCTCGAG
tates were washed three times with immunoprecipitation buffer andAGCCCTGGC (Y121 to F), 59-CCAGCTCATCTGCGCCTTCTGCCAC
once with kinase buffer (10 mM Tris [pH 7.5], 10 mM MgCl2, 100 mMACCCG (Y148 to F). The triple tyrosine mutant was created using
sodium vanadate). Kinase reactions were initiated by the additionall three oligonucleotides in the same reaction. In each case a re-
of 10 mCi 32P-g ATP at 308C. After 10 min the reactions were termi-striction endonuclease site was introduced to facilitate mutant
screening. nated with SDS-containing sample buffer.
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For second-cycle immunoprecipitations, sample buffer±termi- Erpel, T., and Courtneidge, S.A. (1995). Src family protein tyrosine
kinases and cellular signal transduction pathways. Curr. Opin. Cellnated kinase reactions were diluted in immunoprecipitation buffer
to a final SDS concentration of 0.1%. The samples were incubated Biol. 7, 176±182.
with polyclonal antibodies directed toward Abl (pex5) or RIN1N for 1 Feller, S.M., Ren, R., Hanafusa, H., and Baltimore, D. (1994). SH2
hr with subsequent immunoprecipitation using protein A±Sepharose and SH3 domains as modular adhesives: the interaction of Crk and
beads. The samples were washed three times with immunoprecipi- Abl. Trends Biochem. Sci. 19, 453±458.
tation buffer and were eluted using sample buffer. Feng, G.S., Ouyang, Y.B., Hu, D.P., Shi, Z.Q., Gentz, R., and Ni, J.
Autokinase activity and RIN1 phosphorylation was analyzed by (1996). Grap is a novel SH3-SH2-SH3 adaptor protein that couples
SDS-PAGE (10% polyacrylamide). The gels were incubated in fixing tyrosine kinases to the Ras pathway. J. Biol. Chem. 271, 12129±
solution (10% acetic acid, 10% methanol) for 10 min and then were 12132.
treated with 1 M potassium hydroxide for 2 hr at 558C. After alkali
Franz, W.M., Berger, P., and Wang, J.Y.J. (1989). Deletion of antreatment the gels were treated in fixing solution, dried, and sub-
N-terminal regulatory domain of the c-abl tyrosine kinase activatesjected to autoradiography.
its oncogenic potential. EMBO J. 8, 137±147.
Gishizky, M.L., Johnson-White, J., and Witte, O.N. (1993). EfficientAnalysis of RIN1 in Leukemic Cells
transplantation of BCR/ABL induced chronic myelogenous leuke-The human Ph1-positive leukemic cell lines KCL22 (CML in
mia-like syndrome inmice. Proc.Natl. Acad. Sci. USA 90, 3755±3759.lymphoblast crisis), K562 (CML in erythroblast crisis), and ALL1 (ALL
Goga, A., McLaughlin, J., Afar, D.E.H., Saffran, D.C., and Witte, O.N.in lymphoblast crisis) were grown in RPMI supplemented with 10%
(1995). Alternative signals to RAS for hematopoietic transformationfetal bovin serum (FBS). Lysates were prepared from 5 3 107 cells
by the BCR-ABL oncogene. Cell 82, 981±988.using 5 ml of immunoprecipitation buffer. RIN1 and P210 BCR-
ABL were immunoprecipitated with anti-RIN1N and anti-Abl (pex5) Han, L., and Colicelli, J. (1995). A human protein selected for interfer-
polyclonal antibodies, respectively. The immunoprecipitates were ence with ras function interacts directly with ras and competes with
subjected to immune complex kinase assays as described above raf1. Mol. Cell. Biol. 15, 1318±1323.
or were analyzed by Western blotting using monoclonal antibodies Han, L., Wong, D., Dhaka, A., Afar, D., White, M., Xie, W., Herschman,
directed to phosphotyrosine, RIN1, and Abl. H., Witte, O., and Colicelli, J. (1997). Protein binding and signaling
properties of RIN1 suggest a unique effector function. Proc. Natl.
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